Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Sarcoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Pharyngeal Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1PRETEXT I Hepatoblastoma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Mesothelial 1Mouth Neoplasms 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Erdheim-Chester Disease 1Endometrial Adenocarcinoma 1Endocrine Gland Neoplasms 1

Interventions

Nivolumab 6Ipilimumab 2Gemcitabine 2zaleplon 1temsirolimus 1relatlimab 1regorafenib 1olaparib 1linrodostat 1Vorinostat 1Trastuzumab 1Standard of Care 1Sirolimus 1Rehabilitation 1Psychotherapy 1Paclitaxel 1Oxaliplatin 1Niacin 1IFL protocol 1Health Services Needs and Demand 1Everolimus 1Clinical Trials, Phase IV as Topic 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancer × temsirolimus × 1 year × Clear all
NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
249 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡